title: Drug industry. For Mexican antivenom maker, U.S. market is a snake pit.
authors.forename: Lizzie
authors.initials: L
authors.lastname: Wade
mesh_terms: D000818:Animals; D000997:Antivenins / Q000191:economics* / Q000627:therapeutic use; D003435:Crotalid Venoms / Q000037:antagonists & inhibitors*; D017839:Crotalus; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use; D040541:Marketing / Q000331:legislation & jurisprudence*; D008800:Mexico; D012909:Snake Bites / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000997:Antivenins; D003435:Crotalid Venoms; C431183:Crotalidae Polyvalent immune Fab; D007140:Immunoglobulin Fab Fragments; C585824:anavip